[(2R,3R,4S,5R,6R)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl] (2S)-2-amino-4-methylpentanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 糖脂
• 英文名称: [(2R,3R,4S,5R,6R)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl] (2S)-2-amino-4-methylpentanoate
• 化学式: C₁₈H₃₃NO₁₂
• 分子量: 455.5
• InChiKey: LZPHBHSAYSLZIR-KFGMPHPGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  222
• 氢给体数：
  8
• 氢受体数：
  13

文献信息

• DRY POWDER TREPROSTINIL FOR THE TREATMENT OF PULMONARY HYPERTENSION
  申请人：Liquidia Technologies, Inc.

  公开号：EP3452170A1

  公开（公告）日：2019-03-13
• [EN] DRY POWDER TREPROSTINIL FOR THE TREATMENT OF PULMONARY HYPERTENSION<br/>[FR] POUDRE SÈCHE DE TRÉPROSTINIL POUR LE TRAITEMENT DE L'HYPERTENSION PULMONAIRE
  申请人：LIQUIDIA TECH INC

  公开号：WO2017192993A1

  公开（公告）日：2017-11-09

  A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.